Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Ausbruch – startet jetzt die massive FDA-Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D9Z4 | ISIN: US2936024056 | Ticker-Symbol:
NASDAQ
17.04.24
21:53 Uhr
0,630 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENSYSCE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
ENSYSCE BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur ENSYSCE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.04.Ensysce Biosciences, Inc.: Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference244SAN DIEGO, CA / ACCESSWIRE / April 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe...
► Artikel lesen
29.03.Ensysce Biosciences, Inc. - 8-K, Current Report1
26.03.Ensysce Biosciences, Inc. - S-1/A, General form for registration of securities1
19.03.Ensysce Biosciences Inc reports results for the quarter ended in December - Earnings Summary2
15.03.Ensysce Biosciences reports Q4 results1
15.03.Ensysce Biosciences, Inc. - 8-K, Current Report1
15.03.Ensysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results250Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical PlansSAN DIEGO, CA / ACCESSWIRE / March 15, 2024 /...
► Artikel lesen
27.02.Ensysce Biosciences, Inc.: Ensysce Biosciences Receives Positive Nasdaq Listing Determination230SAN DIEGO, CA / ACCESSWIRE / February 27, 2024 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety...
► Artikel lesen
21.02.Ensysce receives FDA guidance on opioid with overdose protection3
21.02.Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection257~ PF614-MPAR program receives FDA guidance ~SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative...
► Artikel lesen
15.02.Ensysce Biosciences reports promising PF614 study results1
15.02.Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript470Publication Details Positive Results of Clinical Study PF614-102SAN DIEGO, CA / ACCESSWIRE / February 15, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)(OTC PINK:ENSCW) ("Ensysce" or "Company"), a clinical-stage...
► Artikel lesen
14.02.Ensysce Biosciences, Inc. - 8-K, Current Report1
13.02.Ensysce Biosciences falls on exercise of warrants for $4.7M gross proceeds2
13.02.Ensysce Biosciences exercises rights to buy shares at a lower price1
13.02.Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds264SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug...
► Artikel lesen
06.02.Ensysce Biosciences, Inc.: Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference254~ PF614-MPAR recognized as potential medical breakthrough ~SAN DIEGO, CA / ACCESSWIRE / February 6, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company...
► Artikel lesen
31.01.Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain314~ PF614 Phase 3 Program Expected to Begin Enrollment in Mid-2024 ~SAN DIEGO, CA / ACCESSWIRE / January 31, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage...
► Artikel lesen
25.01.Ensysce Biosciences, Inc.: Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting298SAN DIEGO, CA / ACCESSWIRE / January 25, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription...
► Artikel lesen
23.01.Ensysce rallies 22% on FDA update for overdose-resistant opioid2
Seite:  Weiter >>
70 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1